Engineered cord blood-derived NK cells expressing a TGFβ dominant-negative receptor-2 (TGF-β DNRII), significantly undermined the inhibitory effects of the tumor microenvironment induced by TGFβ. This evidence concerns the gene TGFB1 and neoplasm.